BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20443131)

  • 1. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
    Kitange GJ; Carlson BL; Schroeder MA; Decker PA; Morlan BW; Wu W; Ballman KV; Giannini C; Sarkaria JN
    J Neurooncol; 2010 Nov; 100(2):177-86. PubMed ID: 20443131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
    Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
    Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
    Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
    Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
    Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
    Schäfer A; Teufel J; Ringel F; Bettstetter M; Hoepner I; Rasper M; Gempt J; Koeritzer J; Schmidt-Graf F; Meyer B; Beier CP; Schlegel J
    Neuro Oncol; 2012 Dec; 14(12):1452-64. PubMed ID: 23132408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.